/ml) were stimulated with CLEC-2 mAb (a) or rhodocytin (b) in the presence and in the absence of 2 U/ml apyrase or 10 M indomethacin and allowed to aggregate.
Representative traces with 3-10 g/ml CLEC-2 mAb and 10-30 nM rhodocytin are shown.
SUPPLEMENTARY FIGURE 2.
Lack of effect of SNP on CLEC-2-dependent platelet aggregation and tyrosine phosphorylation-The effect of SNP (100 M) on CLEC-2 mAb-dependent platelet aggregation (a) and tyrosine phosphorylation (b) was studied. Washed platelets (2x10 8 /ml) were treated as indicated for 3 minutes prior to activation with mAb and allowed to aggregate (a). Washed platelets (4x10 8 /ml) treated with of apyrase (2 U/ml), indomethacin (10 M) and lotrafiban (10 M) were added with SNP (100 M) in comparison with PGI 2 (1 M) and stimulated with 10 g/ml CLEC-2 mAb for 3 minutes prior to lysis. Aliquots were analysed by SDS-PAGE and blots were probed with anti phospho-tyrosine monoclonal antibody (clone 4G10) (b).
SUPPLEMENTARY FIGURE 3.

Effect of cyclic nucleotide-elevation on CLEC-2-dependent platelet aggregation and tyrosine
phosphorylation in human platelets-The effect of PGI2 (0.1 M), GSNO and SNP (100 M)
on rhodocytin-induced platelet aggregation (a) and tyrosine phosphorylation (b) was studied.
Washed platelets (2x10 8 /ml) were treated as indicated for 3 minutes prior to activation with mAb and allowed to aggregate (a). Washed platelets (5x10 8 /ml) treated with apyrase (2 U/ml), indomethacin (10 M) and lotrafiban (10 M) were treated with PGI 2 (1 M), GSNO or SNP (100 M) and stimulated with 300nM rhodocytin for 3 minutes prior to lysis. Aliquots were analysed by SDS-PAGE and blots were probed with anti phospho-tyrosine monoclonal antibody (clone 4G10) (b).
SUPPLEMENTARY FIGURE 4.
Rhodocytin-dependent tyrosine phosphorylation is partially reduced by cyclic nucleotideelevation-The effect of cyclic nucleotide-elevation on rhodocytin-dependent tyrosine
phosphorylation was assessed by use of PGI 2 (2 M) and GSNO (100 M) in the presence of apyrase (2 U/ml), indomethacin (10 M) and lotrafiban (10 M). Washed platelets /ml washed platelets were treated with EHT1864 (50M), before spreading on podoplanin-coated coverslips (10g/ml). Coverslips were fixed, mounted and imaged as described in Figure 4 (c). A suspention of platelets (10 9 /ml) was activated by CLEC-2 mAb (10g/ml) for 45 min in the presence or absence of 1M PGI 2 and Rac activation was studied by GTP-Rac pull down assay using a commercially available kit according to manufacturer's instructions. A positive control for Rac activation was prepared by incubating platelets in parallel with GTPS as specified in the kit manual (not shown). Pulled down beads were analyzed by SDS-PAGE (10%) and blots were probed for Rac1(d) (n=3).
Washed platelets (4x10 8 /ml) were activated with 10 g/ml CLEC-2 mAb in the presence or absence of PGI 2 (1M) or GSNO (1mM) and lysed after 3, 20, 45 or 60 min with 5x Laemmli sample buffer. Aliquots were analysed by SDS-PAGE prior to probing with anti VASP pSer239. The antibody was then stripped and the membranes reprobed for VASP p-Ser157 and PLC2 for loading control (n=2).
